A computer generated image of the Ebola virus
A computer generated image of the Ebola virus
… Great Progress In The Fight Against The Deadly Ebola Virus …

MERCK DEVELOPS FIRST REGULATORY APPROVED AND LICENSED EBOLA VACCINE: ERVEBO

Another vaccine breakthrough by Merck

John G. Baresky

Elements of innovation to combat the Ebola virus:

  • FDA and CHMP approves Merck’s Ebola vaccine “Ervebo”
  • The FDA had Ervebo’s review slated for review in the first quarter of 2020 and then re-prioritized it so it’s approval was completed in mid- December 2019
  • The Merck Ebola vaccine is administered via a single injection
  • Ervebo is genetically engineered to express a glycoprotein from the Zaire Ebola virus so as to provoke a neutralizing immune response
  • Johnson & Johnson has an Ebola vaccine currently deployed in Africa as a government authorized emergency measure prior to its approval by regulators

Merck ( NYSE: MRK ) has announced its Ebola vaccine, Ervebo, has been approved by European regulators ( followed with approval by the FDA )

The product, which has already been deployed in its investigational format in the Democratic Republic of Congo ( DRC ), was cleared by Europe’s “Committee For Medicinal Products for Human Use ( CHMP )” as well as the FDA in the United States. It will be manufactured in Germany. Merck anticipates it will be able to start shipping Ervebo product to customers by the 3rd quarter of 2020.

Ervebo’s journey from development to approval

The development of Ervebo was a clinical research and product licensing journey. Canada’s National Microbiology Laboratory was the original developer of the immunization which it then licensed to NewLink Genetics of Ames, Iowa. When the 2014 Ebola outbreak was triggered, Merck licensed it and went to work on further developing the vaccine along with other collaborators.

Ervebo is genetically engineered

Ervebo is an advanced product that is the result of rigorous research and development efforts. It is genetically engineered to express a glycoprotein from the Zaire ebolavirus so as to provoke a neutralizing immune response to the Ebola virus. Merck was able to not only fully prove the efficacy of the immunization but also demonstrate its ability to mass-produce it at premium quality levels to assure the reliability and safety of the product.

An ongoing threat of Ebola outbreak surpasses a year

Since it first started in August 2018, the present Ebola outbreak underway has killed more than 2,100 people. It is in the northeastern portion of the country, in North Kivu and Ituri provinces. Over 3,000 cases have been reported; Ebola has demonstrated its contagious abilities with 1,000 cases in the first month, then in a 90-day period ( April through June 2019 ) another 1,000 cases surfaced.

Why and how Ebola is such an enormous health threat

Ebola Virus Disease ( EVD ) is an uncommon and deadly disease in people and nonhuman primates. Viruses causing EVD are found primarily in sub-Saharan Africa. People can get EVD through direct contact with an infected animal (bat or nonhuman primate) or person; including the dead bodies of EVD victims.

Due to its deadly attributes ( Ebola mortality rate is 50% to 90% ) as well as contagious makeup, Ebola is a major challenge for not only the individuals it infects initially but also a ruthless danger for caregivers and medical professionals of Ebola patients who must also take thorough precautions to protect themselves

The Ebola virus creates further issues as it causes severe inflammation and tissue damage for survivors to contend with through recovery. Ebola is persistent as it has been detected in patients several months after their recovery.

Government and healthcare leaders limited to a single strategy for Ebola outbreaks until a vaccine was developed

Ebola outbreaks, small or large, were dealt with in a methodical process centered on containment and control. Identify infected cases, isolate them, then separately find those in closest contact to the infected individuals and monitor or isolate them as well. Carefully care for those infected and take all precautions necessary when handling the corpses of victims as they are still contagious. Control the number of persons traveling into locales where outbreaks are present and assess those leaving those locales to be certain they have not been exposed to Ebola.

Ebola’s primary origins, host carriers and transmission conduits continue to warrant research

It has been long believed fruit bats are the primary hosts of the Ebola virus although diligent research continues that includes the potential of insects ( which bats consume ), rodents and small mammals as hosts or widespread carriers of the virus.

This drives researchers to continue to search for more than one host beyond the fruit bat as an Ebola host. Given the rich biological environment of the Congo region, amazing diversity of wildlife in Africa as well as migrating populations of various species, this compounds the challenges involved with host identification

Ebola’s Deadly History

The Ebola virus was initially discovered in 1976 near the Ebola River in DRC. Over the last 40 years, there have been roughly 10 severe Ebola outbreaks and several less severe, isolated incidences. Previous to the current outbreak ( which is now ranked as the second-worst to date) the West African Ebola epidemic was so severe that it resulted in about 30,000 EVD cases and more than 11,000 deaths between 2014 and 2016.

Merck is a global leader in vaccine immunization development

The commercial development of Ervebo is another clinical and commercial vaccine product victory for Merck who has had a long-standing commitment to global vaccine development. Its HPV STD and Oncology vaccine, Gardasil, has saved millions of lives and generated considerable savings for consumers, medical professionals and payers.

A second Ebola vaccine producer needs to enter the market

Additional options from other vaccine manufacturers and research organizations are necessary in order to stockpile product in the event Merck is unable to produce their product as well as to embark on a large scale immunization initiative to thwart Ebola outbreaks prior to their occurrence.

Written by

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store